title: Blood lactate is reduced following successful treatment of anaemia in haemodialysis patients with recombinant human erythropoietin both at rest and after maximal exertion.
abstract: The effect of increasing haemoglobin by erythropoietin therapy on exercise capacity was investigated in 11 regular haemodialysis patients, previously transfusion dependent. Exercise work load increased from a median of 100 W (95% confidence limit, 25-135) to 120 (45-180; p < 0.05) following erythropoietin, and the duration of the exercise test from 13 (3.5-20) to 15.5 min (4-22; p < 0.05). Resting blood lactate concentration decreased from 0.8 (0.6-1.6) to 0.3 mmol/l (0.3-0.4), p < 0.05, following treatment with erythropoietin, as did blood lactate concentration at maximal exertion from 2.0 (1.0-4.1) to 1.8 mmol/l (0.5-2.8; p < 0.05). In association with the increase in haemoglobin from a median of 6 (5.1-6.8) to 11.1 g/dl (11-11.9) following erythropoietin therapy, patients were able to achieve greater exercise capacity both in terms of maximum work load and duration of exercise in association with a reduced resting arterial lactate and a similar exercise-induced lactate production. This suggests that treatment had improved muscle function in terms of lactate production and/or utilisation. This was probably due to the increase in tissue oxygen delivery, as there was an increase in the median arterial oxygen content from 79 (65-85) to 150 ml O2 (144-157) following erythropoietin treatment.
authors: Department of Renal Medicine, St. James's University Hospital, Leeds, UK.
authors: A
authors: A
authors: Davenport
authors: E J
authors: EJ
authors: Will
authors: S K
authors: SK
authors: Khanna
authors: A M
authors: AM
authors: Davison
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000740:Anemia / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D003131:Combined Modality Therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D005080:Exercise Test / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D007773:Lactates / Q000097:blood*; D019344:Lactic Acid; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion / Q000187:drug effects* / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D012146:Rest / Q000502:physiology*
chemical_list: D007773:Lactates; D011994:Recombinant Proteins; D004921:Erythropoietin; D019344:Lactic Acid